BMRNBioMarin Pharmaceutical Inc.
Is it safe?
Strong, no red flags: a safe balance sheet and clean books.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$1.2M, 90 days to Oct 9, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -62% · now 22% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BMRN take a bad year?
BioMarin Pharmaceutical Inc. carries $4.03B of net debt at 19.6× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 19.6×
Net debt / EBITDA · −0.99× a year ago · the load is going up
- Altman Z-score
- 5.55
Altman Z-score · safe zone, above 3
- Interest cover
- 1.97×
Interest cover · operating profit barely covers the interest bill
Details›
- Total debtQ2 2026
- $4.91B
- Cash and short-term investments
- $874M
- Net debt
- $4.03B
- EBITDA, trailing twelve months
- $206M
- Operating profit, trailing twelve months
- $149M
- Debt / equity
- 0.78×
- Total debt / EBITDA
- 23.8×
- Annualised volatilitytwo years of daily moves
- 33%
- Worst drawdown on file
- −62%
- Below its 52-week high
- 22%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.